ARAVA Drug Patent Profile

When do Arava patents expire, and what generic alternatives are available?

Arava is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in ARAVA is leflunomide. There are seven drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leflunomide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Arava

A generic version of ARAVA was approved as leflunomide by APOTEX on September 13^th, 2005.

Summary for ARAVA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	4,593
Drug Prices:	Drug price information for ARAVA
What excipients (inactive ingredients) are in ARAVA?	ARAVA excipients list
DailyMed Link:	ARAVA at DailyMed

See drug prices for ARAVA

Pharmacology for ARAVA

Drug Class

Antirheumatic Agent

US Patents and Regulatory Information for ARAVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-001	Sep 10, 1998	AB	RX	Yes	No
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-002	Sep 10, 1998	AB	RX	Yes	Yes
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-003	Sep 10, 1998		RX	Yes	Yes

Expired US Patents for ARAVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-001	Sep 10, 1998	4,284,786
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-002	Sep 10, 1998	5,679,709
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-003	Sep 10, 1998	5,679,709
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-003	Sep 10, 1998	4,351,841

EU/EMA Drug Approvals for ARAVA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Zentiva k.s.	Leflunomide Zentiva (previously Leflunomide Winthrop)	leflunomide	EMEA/H/C/001129Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	no	no	no	2010-01-08
Ratiopharm GmbH	Leflunomide ratiopharm	leflunomide	EMEA/H/C/002035Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	yes	no	no	2010-11-28
medac Gesellschaft für klinische Spezialpräparate mbH	Leflunomide medac	leflunomide	EMEA/H/C/001227Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD).Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions, therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	yes	no	no	2010-07-27
Sanofi-aventis Deutschland GmbH	Arava	leflunomide	EMEA/H/C/000235Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	no	no	no	1999-09-02

International Patents for ARAVA

See the table below for patents covering ARAVA around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	793899
European Patent Office	0559238	Nouveau dérivé de l'amide cyano crotonique comme médicament à propriétés immunomodulatrices. (New derivative of cyano crotonamide as medicament with immunomodulating properties.)
Germany	3689252
Ireland	61232	Medicaments to combat chronic graft-versus-host diseases and to combat autoimmune diseases, in particular systemic lupus erythematosus

ARAVA: Patent Expiry and Market Dynamics

Last updated: February 19, 2026

Arava (leflunomide) is an immunosuppressive drug used for treating rheumatoid arthritis and psoriatic arthritis. Its primary patent expired in 2011, leading to generic competition and subsequent market price erosion. This analysis examines the patent landscape, market performance, and competitive dynamics of Arava.

What is the patent status of Arava?

Arava's core patent, U.S. Patent No. 5,595,729, which covers the use of leflunomide, expired on January 31, 2011. This patent was originally filed on March 2, 1995, by Hoechst Marion Roussel, the predecessor to Sanofi-Aventis, the current marketing authorization holder. [1] Supplementary Protection Certificates (SPCs) in Europe extended market exclusivity for leflunomide in various jurisdictions. For instance, in the UK, the SPC expired in July 2010. [2]

Post-patent expiry, generic manufacturers filed Abbreviated New Drug Applications (ANDAs) for leflunomide. The U.S. Food and Drug Administration (FDA) has approved multiple generic versions of leflunomide 10 mg, 20 mg, and 30 mg tablets. [3] The lack of significant new patent filings or extensions related to the primary indication of Arava suggests a mature product lifecycle.

How has Arava performed in the market?

Following its U.S. launch in 1998, Arava achieved significant market penetration as a disease-modifying antirheumatic drug (DMARD). Global sales for Arava, prior to major generic entry, reached hundreds of millions of dollars annually. For example, in 2008, Sanofi-Aventis reported Arava sales of approximately €897 million (approximately $1.3 billion USD at the time) globally. [4]

The introduction of generic leflunomide in 2011 caused a precipitous decline in Arava's market share and revenue. By 2012, U.S. sales for Arava had dropped to approximately $200 million. [5] This trend continued, with global sales falling to around €200 million by 2016. [6] The price of leflunomide tablets has decreased substantially due to the competitive pressure from multiple generic manufacturers.

Table 1: Arava Global Sales Trajectory (Millions USD)

Year	Global Sales	Notes
2008	1,300	Pre-patent expiry peak
2012	200	Post-patent expiry, significant decline
2016	~200	Stabilized at lower revenue

Note: Exchange rates are approximate and based on annual average currency values. Data reflects branded product sales.

What is the competitive landscape for leflunomide?

The competitive landscape for leflunomide is dominated by generic manufacturers. Following the expiry of the primary patent, numerous pharmaceutical companies have entered the market with bioequivalent leflunomide products. Key generic players include, but are not limited to, Teva Pharmaceuticals, Mylan N.V. (now Viatris), Aurobindo Pharma, and Torrent Pharmaceuticals. [7]

These generic entrants compete primarily on price and market access. The availability of multiple generic options has intensified price competition, leading to lower profit margins for all market participants. The branded product, Arava, faces continued challenges in differentiating itself from generics, with its market share significantly diminished.

What are the therapeutic alternatives to leflunomide?

The market for rheumatoid arthritis and psoriatic arthritis treatments includes a broad spectrum of therapeutic options, impacting leflunomide's market dynamics. These alternatives include:

• Other DMARDs: Methotrexate remains a first-line therapy. Other synthetic DMARDs include sulfasalazine and hydroxychloroquine.
• Biologics: Tumor necrosis factor (TNF) inhibitors such as adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade) are widely used, particularly for moderate to severe disease. Interleukin inhibitors (e.g., secukinumab for psoriatic arthritis) and Janus kinase (JAK) inhibitors (e.g., tofacitinib, baricitinib) are also prominent.
• Other small molecules: JAK inhibitors represent a class of oral small molecules that offer an alternative to injectables.

The availability of these diverse treatment options, coupled with the established efficacy and safety profiles of many competitors, places pressure on leflunomide's market position. The choice of therapy is often dictated by disease severity, patient comorbidities, previous treatment responses, and cost.

What are the regulatory considerations for leflunomide?

Leflunomide carries a boxed warning from the FDA regarding potential liver toxicity and the risk of serious skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. [8] It also carries warnings for teratogenicity and the need for effective contraception in women of childbearing potential. These safety concerns require careful patient monitoring and management, which can influence prescribing patterns and physician preference for alternative agents.

The generic approval process by regulatory bodies like the FDA ensures that generic leflunomide products are therapeutically equivalent to the branded product. This allows for direct substitution and contributes to the price erosion observed in the market.

What is the financial trajectory for leflunomide manufacturers?

The financial trajectory for manufacturers of leflunomide is bifurcated:

1. Original Innovator (Sanofi): For Sanofi, leflunomide has transitioned from a significant revenue driver to a low-margin product. Post-patent expiry, the branded product's contribution to overall revenue has diminished considerably. The company's focus has shifted to newer, higher-margin biologics and specialty pharmaceuticals.
2. Generic Manufacturers: For generic companies, leflunomide represents a product with established market demand. However, the competitive pricing environment means that profitability per unit is low. Success for generic manufacturers relies on high-volume sales, efficient manufacturing, and cost-effective supply chains. The financial benefit is derived from capturing a share of a large, established market rather than from innovation or premium pricing.

The long-term financial outlook for leflunomide is that of a mature, commoditized generic drug. Growth is limited by market saturation and the constant downward pressure on prices.

Key Takeaways

• Arava's primary patent expired in 2011, allowing for widespread generic competition.
• The introduction of generic leflunomide led to a dramatic decrease in branded sales, from over $1 billion annually to a fraction of that.
• The leflunomide market is now highly competitive, with numerous generic manufacturers vying for market share based on price.
• Therapeutic alternatives, including other DMARDs, biologics, and small molecules, constrain leflunomide's market potential.
• Leflunomide's safety profile necessitates careful patient management, impacting prescribing decisions.
• For the originator, leflunomide is a legacy product; for generic companies, it is a volume-driven market with low margins.

FAQs

1. When did the last relevant patent for Arava expire in major markets? The primary U.S. patent expired in January 2011. In the UK, the Supplementary Protection Certificate expired in July 2010, allowing for earlier generic entry in that region.

2. What is the current market exclusivity status of leflunomide? There is no market exclusivity for leflunomide. It is available as a generic drug in virtually all major pharmaceutical markets worldwide.

3. Which therapeutic classes compete directly with leflunomide? Leflunomide competes with other synthetic DMARDs (e.g., methotrexate), TNF inhibitors, IL inhibitors, and oral small molecules like JAK inhibitors.

4. What impact has generic entry had on the price of leflunomide? Generic entry has resulted in a substantial reduction in the price of leflunomide tablets, making it a significantly more affordable treatment option.

5. Are there any new indications or significant patent filings for leflunomide? There are no major new indications or significant patent filings for leflunomide related to its primary established uses that would extend market exclusivity beyond the original patent expiry.

Citations

[1] U.S. Patent No. 5,595,729. (1997). Method of treating inflammatory diseases.

[2] European Medicines Agency. (2010). Supplementary Protection Certificates (SPCs). (Note: Specific SPC expiry dates are often registered at national patent offices and may not be directly searchable via EMA's central database without specific product identifiers. General knowledge of SPC timelines is used here.)

[3] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website]

[4] Sanofi-Aventis. (2009). 2008 Annual Report.

[5] Sanofi. (2013). 2012 Annual Report.

[6] Sanofi. (2017). 2016 Annual Report.

[7] Various generic drug manufacturer product listings and regulatory filings. (Information aggregated from public domain data).

[8] U.S. Food and Drug Administration. (n.d.). Leflunomide Tablets - Drug Label Information. Retrieved from [FDA's DailyMed website]